|
|
|
|
| Symbol(s): |
BMTI |
| Date: |
7-Feb-10 |
| Contributor: |
PriceTarget Research, Inc. |
| Title: |
BioMimetic has a current Overall Rating of C (Neutral). |
| Document Size: |
7 pages |
| Price: |
$25 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $25. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| BioMimetic has a current Overall Rating of C (Neutral). Power Rating (62) is high; appreciation potential (6) is negative. Relative to the S&P 500 Composite, BioMimetic Therapeutics Inc has both Growth and Value characteristics -- its appeal is likely to be to Capital Gain-oriented investors. BMTI is of average investment quality. BMTI's current technical position is very strong. BMTI's Power Rating is 62. However, the trend in BMTI's earnings estimates has been unfavorable in...
| | |
|
|
